Lumos Diagnostics Holdings Limited (LDX.AX)

ASX - ASX Delayed price. Currency in AUD

Add to watchlist

0.0530

+0.0040

(+8.16%)

At close: 04:10PM AEST

Loading interactive chart…

Simply Wall St.
Lumos Diagnostics Holdings Full Year 2023 Earnings: US$0.038 loss per share (vs US$0.30 loss in FY 2022)
Lumos Diagnostics Holdings ( ASX:LDX ) Full Year 2023 Results Key Financial Results Revenue: US$10.5m (down 9.4% from...
PR Newswire
Lumos Receives US FDA Clearance for FebriDx®
Lumos Diagnostics (ASX: LDX), ("Lumos" or the "Company") a leader in rapid, point-of-care (POC) diagnostic technologies, is pleased to announce that it has received clearance from the US Food and Drug Administration (FDA) to market its FebriDx® rapid, point-of-care test in the United States.